PubRank

Ie-Ming Shih

Author PubWeight™ 267.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010 13.07
2 Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010 10.78
3 The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010 7.27
4 TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013 6.88
5 Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003 5.64
6 Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011 5.53
7 Ovarian cancer. Annu Rev Pathol 2009 4.92
8 Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009 3.90
9 The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A 2002 3.46
10 Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004 3.35
11 Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008 3.22
12 Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009 2.94
13 Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005 2.83
14 Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006 2.76
15 ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011 2.71
16 Notch3 gene amplification in ovarian cancer. Cancer Res 2006 2.66
17 Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010 2.65
18 Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008 2.60
19 MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008 2.60
20 Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013 2.58
21 National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008 2.44
22 Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011 2.41
23 Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 2012 2.27
24 Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 2008 2.26
25 Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009 2.25
26 Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002 2.18
27 Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012 2.09
28 Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011 2.03
29 Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 2008 2.01
30 TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 2011 1.94
31 Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 2002 1.90
32 Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003 1.78
33 Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002 1.72
34 DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010 1.71
35 Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 2009 1.71
36 Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007 1.70
37 The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007 1.70
38 Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004 1.66
39 Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006 1.62
40 Increased plasma DNA integrity in cancer patients. Cancer Res 2003 1.59
41 Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003 1.58
42 Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2011 1.56
43 Principle and applications of digital PCR. Expert Rev Mol Diagn 2004 1.55
44 Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005 1.55
45 A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A 2006 1.52
46 Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010 1.45
47 Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010 1.44
48 Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010 1.44
49 Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013 1.41
50 Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006 1.41
51 Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010 1.39
52 Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011 1.37
53 Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009 1.36
54 APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002 1.35
55 Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009 1.34
56 IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009 1.33
57 Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 2006 1.32
58 Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004 1.27
59 BACOM: in silico detection of genomic deletion types and correction of normal cell contamination in copy number data. Bioinformatics 2011 1.26
60 Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012 1.26
61 Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 2013 1.25
62 Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol 2010 1.24
63 Ovarian Cancer Is an Imported Disease: Fact or Fiction? Curr Obstet Gynecol Rep 2012 1.23
64 Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia 2012 1.22
65 Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005 1.22
66 Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer. Oncotarget 2010 1.21
67 Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 2009 1.20
68 Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol 2006 1.18
69 A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014 1.17
70 Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007 1.16
71 The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res 2008 1.16
72 NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res 2007 1.16
73 Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011 1.15
74 Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006 1.14
75 Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012 1.13
76 HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003 1.13
77 Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem 2010 1.10
78 Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 2008 1.07
79 Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol 2010 1.07
80 Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 2010 1.06
81 Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J Am Chem Soc 2010 1.05
82 Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 2004 1.04
83 Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Hum Pathol 2005 1.04
84 Homogeneous point mutation detection by quantum dot-mediated two-color fluorescence coincidence analysis. Nucleic Acids Res 2006 1.03
85 Genome-wide identification of significant aberrations in cancer genome. BMC Genomics 2012 1.03
86 Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol 2012 1.02
87 Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 2008 1.02
88 HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002 1.02
89 Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. BMC Syst Biol 2014 1.02
90 MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol 2007 1.01
91 Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 2006 1.00
92 Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol 2013 1.00
93 Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer 2013 0.99
94 Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol 2011 0.99
95 p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009 0.99
96 Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013 0.99
97 Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 2009 0.98
98 Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 2009 0.98
99 Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2011 0.98
100 Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol 2007 0.97
101 Defining NOTCH3 target genes in ovarian cancer. Cancer Res 2012 0.97
102 Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 2011 0.97
103 Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol 2007 0.96
104 The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol 2012 0.96
105 Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Mod Pathol 2011 0.96
106 DDN: a caBIG® analytical tool for differential network analysis. Bioinformatics 2011 0.96
107 Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol 2009 0.95
108 Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor--an aid in differential diagnosis. Am J Surg Pathol 2006 0.95
109 The diagnostic role of claudins in serous effusions. Am J Clin Pathol 2007 0.95
110 Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012 0.94
111 Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 2007 0.94
112 Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol 2014 0.94
113 Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance. Proteomics Clin Appl 2009 0.93
114 Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 2011 0.93
115 Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology. Phys Biol 2011 0.93
116 NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells. Cancer Res 2012 0.93
117 Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 2007 0.93
118 Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 2006 0.92
119 Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis 2012 0.92
120 Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update. J Obstet Gynaecol Res 2014 0.92
121 HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005 0.90
122 Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol 2014 0.90
123 Differential expression of L-selectin ligand in the endometrium during the menstrual cycle. Fertil Steril 2005 0.90
124 Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol 2007 0.89
125 Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin. Am J Pathol 2002 0.89
126 RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer 2013 0.89
127 Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecol Oncol 2012 0.89
128 RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res 2014 0.89
129 Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 2006 0.89
130 Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol 2013 0.89
131 Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis. Cancer Res 2012 0.88
132 Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol 2016 0.88
133 A fluorescence light-up Ag nanocluster probe that discriminates single-nucleotide variants by emission color. J Am Chem Soc 2012 0.88
134 Knowledge-guided multi-scale independent component analysis for biomarker identification. BMC Bioinformatics 2008 0.88
135 Characterization of the immune cell repertoire in the normal fallopian tube. Int J Gynecol Pathol 2014 0.88
136 Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res 2007 0.87
137 Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 2014 0.87
138 Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites. PLoS One 2012 0.87
139 The roles of ARID1A in gynecologic cancer. J Gynecol Oncol 2013 0.87
140 Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol 2007 0.86
141 Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochim Biophys Acta 2005 0.86
142 Integrative network analysis to identify aberrant pathway networks in ovarian cancer. Pac Symp Biocomput 2012 0.85
143 Immunological localization of syndecan-1 in human endometrium throughout the menstrual cycle. Fertil Steril 2006 0.85
144 Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization. J Clin Endocrinol Metab 2006 0.85
145 HLA-G and immune evasion in cancer cells. J Formos Med Assoc 2010 0.85
146 High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecol Oncol 2012 0.84
147 Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. Hum Pathol 2008 0.84
148 Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93. Am J Pathol 2009 0.84
149 HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions. Am J Surg Pathol 2008 0.84
150 New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol 2010 0.83
151 The role of forkhead box Q1 transcription factor in ovarian epithelial carcinomas. Int J Mol Sci 2012 0.83
152 Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am J Pathol 2012 0.83
153 BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol 2014 0.83
154 Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. Hum Pathol 2011 0.82
155 Polysialic acid enhances the migration and invasion of human cytotrophoblasts. Glycobiology 2012 0.82
156 Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. Int J Gynecol Pathol 2011 0.82
157 Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor. Am J Pathol 2005 0.82
158 Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. Mol Cell Proteomics 2012 0.81
159 Lack of a y-chromosomal complement in the majority of gestational trophoblastic neoplasms. J Oncol 2010 0.81
160 Mapping DNA quantity into electrophoretic mobility through quantum dot nanotethers for high-resolution genetic and epigenetic analysis. ACS Nano 2011 0.81
161 Expression of L-selectin ligands in human endometrium during the implantation window after controlled ovarian stimulation for oocyte donation. Fertil Steril 2006 0.81
162 Mel-CAM (CD146) expression in parotid mucoepidermoid carcinoma. Oral Oncol 2003 0.80
163 Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochim Biophys Acta 2005 0.80
164 Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis. PLoS One 2013 0.80
165 Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Hum Pathol 2008 0.80
166 Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis. Clin Cancer Res 2002 0.80
167 PUGSVM: a caBIG™ analytical tool for multiclass gene selection and predictive classification. Bioinformatics 2010 0.79
168 Digital single-nucleotide polymorphism analysis for allelic imbalance. Methods Mol Med 2005 0.79
169 DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression. J Oncol 2011 0.79
170 AISAIC: a software suite for accurate identification of significant aberrations in cancers. Bioinformatics 2013 0.78
171 Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses. IEEE/ACM Trans Comput Biol Bioinform 2014 0.78
172 Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases. Am J Surg Pathol 2014 0.78
173 Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol 2011 0.77
174 Regulatory component analysis: a semi-blind extraction approach to infer gene regulatory networks with imperfect biological knowledge. Signal Processing 2011 0.77
175 Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. Biochem Biophys Res Commun 2010 0.77
176 Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). Proteomics 2004 0.77
177 Evolution of a trophoblastic tumor from an endometrioid carcinoma--a morphological and molecular analysis. Int J Gynecol Pathol 2011 0.77
178 Seromucinous Tumors of the Ovary. What's in a Name? Int J Gynecol Pathol 2016 0.77
179 Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis. Am J Surg Pathol 2009 0.76
180 Biomarker identification by knowledge-driven multilevel ICA and motif analysis. Int J Data Min Bioinform 2009 0.76
181 Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter? Gynecol Oncol 2010 0.76
182 PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. Int J Gynecol Pathol 2017 0.76
183 Discovery of a cell: reflections on the checkered history of intermediate trophoblast and update on its nature and pathologic manifestations. Int J Gynecol Pathol 2014 0.75
184 Correction: Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. PLoS One 2016 0.75
185 GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol 2015 0.75
186 Bokhman's dualistic model of endometrial carcinoma. Revisited. Gynecol Oncol 2013 0.75
187 GIST: a Gibbs sampler to identify intracellular signal transduction pathways. Conf Proc IEEE Eng Med Biol Soc 2011 0.75
188 Establishing isogenic inducible cell lines using founder reporter lines and recombinase-mediated cassette exchange. Biotechniques 2013 0.75
189 Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions. Expert Opin Med Diagn 2009 0.75
190 Genotype analysis using human hair shaft. Cancer Epidemiol Biomarkers Prev 2002 0.75
191 Uterine epithelioid trophoblastic tumor in an African green monkey (Chlorocebus aethiops sabaeus). J Am Assoc Lab Anim Sci 2007 0.75